Introduction
Antigen-specific activation of T cells is manifested by the interaction of cell surface T cell receptors with antigen presented in the context of class II molecules by antigenpresenting cells (APC) (1) . Optimal activation of T cells also depends on the interaction of a number of co-receptor molecules such as CD4 and CD8 (2, 3) , and co-stimulatory molecules such as CD28 and CD2 (4, 5) with their respective ligands. Activation of T cells, therefore, depends ultimately on multiple interactions of key regulatory surface antigens, the absence of which could lead to diminished immune responses (6) .
Lymphocyte activation gene (LAG)-3, a glycoprotein member of the Ig superfamily, is expressed selectively on activated T cells and NK cells (7) . A recent report suggested that expression of LAG-3 on T cells correlated with a population that predominantly produced IFN-γ (8) . LAG-3 was originally proposed as a counter-receptor for class II due to some sequence homology to CD4, and co-localization of LAG-3 and CD4 genes on the same chromosome in human and Correspondence to: M. Subramanyam Transmitting editor: L. Glimcher Received 10 November 1997, accepted 3 February 1998 mouse (7) . Since then, LAG-3 has been shown to interact with cell surface class II (9) . Additionally, inhibition of rosette formation between CD4-transfected Cos cells and class IIexpressing Daudi cells in the presence of soluble LAG-3-Ig has been demonstrated (10) . Based on the findings that anti-LAG-3 mAb prolonged antigen-specific proliferation of T cell clones (11) and that cross-linked LAG-3-Ig inhibited the proliferation of an antigen-specific T cell clone (12) , LAG-3 was proposed to function as a negative regulator of T cell activation by interacting with class II. Miyazaki et al. (13) , however, have reported a lack of involvement of LAG-3 in class II-restricted lymphocyte selection and function, by creating CD4 and LAG-3 double-deficient mice. Moreover, these authors have also demonstrated that the only detectable defect in mice with a LAG-3 null mutation was the inability of their NK cells to kill certain tumor targets (14) . Surprisingly, other class II-dependent B and T cell functions were not altered in these mice.
To therefore better understand the contribution of LAG-3- ) were stained with LAG-3-Ig, control human IgG and a pan anti-class II mAb, as described in Methods. Viable cells, gated based on propidium iodide exclusion, were acquired and analyzed on the FACSort using the Lysys II program.
class II interaction in the regulation of immune responses, a soluble Ig fusion protein of LAG-3 was generated. A possible role for LAG-3 as an immunosuppressant of naive human CD4 ϩ T cells is described in this paper.
Methods

Cloning of LAG-3-Ig
DNA encoding soluble LAG-3-Ig D1-D4 (comprising of the four extracellular Ig-like domains) was fused to the DNA encoding the IgG1 Fc region. The pCMVTBP-1a IgG fusion construct (prepared in house) was used as the template for amplifying the hIgG1-specific fragment (the IgG1 portion of pCMVTBP originated from a plasmid provided by Dr F. Triebel, Institut Gustave Roussy, Villejuif, France) by standard PCR techniques as described in Huard et al. (12) . Briefly, the fragment corresponding to the D1-D4 domains of LAG-3 was made first by using a pUC D1-D4 template and the following primers: forward primer, TTTTCTCGAGATGTGGGAGGCTCA-GTTCC; reverse primer to generate the D1-D4 molecule with an enterokinase linker and IgG tail, GCTGCCGCTGCCTT-TATCATCATCATCACCTGGGCTAGACAGCTCTGTGAAGTA. The fragments from this PCR were gel purified, denatured and annealed at the enterokinase site. These molecules were then used as templates for generating the fusion protein. PCR amplification was performed with the same forward primer listed above and the following reverse primer: TTTTCT- CGAGTCATTTACCCGGAGACAGGG. PCR fragments were purified, subcloned into pUC18 vector, sequenced using the dideoxy chain termination method, excised as a XhoI fragment and sub-cloned into the pCLH3AXSV2DHFRhαIVSA (Dα) XhoI digested mammalian expression vector. The plasmid Dα contains the mouse metallothionein I promoter, which drives expression of the gene of interest, and the mouse dihydrofolate reductase gene, which was used as the selectable and amplifiable marker (15) . The LAG-3-Ig construct was transfected into CHO-DUKX cells by standard calcium phosphate transfection procedures, subjected to methotrexate selection and cloned. Production of soluble LAG-3-Ig fusion protein from the transfectants was monitored using a LAG-3-Ig specific ELISA.
Purification of LAG-3-Ig
The sLAG-3-Ig fusion protein was produced in a perfusion bioreactor. Crude medium from the bioproduction runs was concentrated by ultrafiltration using a pelicon concentrator and then applied to a Poros Protein A column (PerSeptive Biosystems, Framingham, MA). Bound LAG-3-Ig was eluted with 0.1 M Na citrate, pH 3.5, and then subjected to chromatography on a Sephacryl S300 HR column (Pharmacia, Piscataway, NJ). Purified protein was analyzed by SDS-PAGE, N-terminal sequencing, mass spectroscopy and AAA analysis. By PAGE, LAG-3-Ig fusion protein had the expected mol. wt of 162,300 Da using non-reducing and 81,600 Da using reducing conditions. The protein was also certified endotoxin-free using the Limulus amoebocyte lysate test.
Other reagents
Purified CTLA-4-Ig fusion protein containing a murine IgG2a tail was generated from a NS1 cell line expressing murine CTLA-4-Ig (16) Isolation of peripheral blood mononuclear cells (PBMC) and human mixed lymphocyte response (MLR)
Whole blood from donors was obtained through Interstate Blood Bank (Memphis, TN) and blood specimens were handled as potentially infectious material in a biosafety level 2 containment facility. PBMC were separated from red blood cells and granulocytes by Ficoll-Hypaque (Pharmacia, Uppsala, Sweden) purification. Stimulator PBMC were adjusted to 2-4ϫ10 6 cells/ml in complete medium (RPMI 1640; Gibco, Gaithersburg, MD) containing 10% heat-inactivated human AB serum, 2 mM glutamine, 50 µM 2-mercaptoethanol and 100 U/ml penicillin/100 µg/ml streptomycin) and treated with mitomycin C [25 µg/ml for peripheral blood lymphocytes (PBL); 50 µg/ml for Raji] for 30 min in a 37°C water bath. Human serum, mitomycin C and other supplements were obtained from Sigma (St Louis, MO). To set up autologous stimulation controls, some responder cells were also treated with mitomycin C as described above.
For the one-way allogeneic MLR assay, responder cells were plated at 10 5 cells/well, and stimulator cells at 5ϫ10 4 cells/well (PBL) or 1ϫ10 4 cells/well (Raji) in Falcon 96-well round-bottom plates. Cells were incubated with serial dilutions of the anti-CD4 antibody Leu 3A (Becton Dickinson, San Jose, CA), an isotype-matched control antibody (PharMingen, San Diego, CA), LAG-3-Ig, CTLA-4-Ig or control human IgG at the start of the assay. For time-point experiments, the reagents were added every day at the specified concentrations, for the period of the assay. Cyclosporin A at 1 µg/ml was used as an additional control. Plates were incubated at 37°C in a humidified 5% CO 2 atmosphere for 5-7 days. Proliferation of the cells was determined by pulsing the wells with [ 3 H]thymidine (1 µCi/well) for the last 18 h of the assay. In IL-2 supplementation experiments, 100 U/ml rIL-2 (Sigma) was added to the wells on a daily basis for the duration of the assay. Cytokine measurements were routinely made on day 5 of the MLR using commercially available ELISA kits (R & D Systems, Minneapolis, MN).
Xenogeneic MLR
For the mouse-human xeno assays, murine A20 B lymphoma cells (ATCC, Rockville, MD) were used as stimulators (1ϫ10 4 cells/well) and primary human PBL as responders (1ϫ10 5 cells/well). Cells were washed and resuspended in complete medium described above containing 10% fetal bovine serum (Gibco) instead of human serum. Proliferation of the cells was determined after 4 days as described above.
Recall antigen and superantigen stimulation assays
For these assays, PBMC (10 5 cells/well) were stimulated in the absence or presence of LAG-3-Ig or control human IgG with the following antigens: tetanus toxoid (50 µg/ml, TT, Public Health Biologic Laboratories, Boston, MA), toxic shock syndrome toxin-1 (1 µg/ml, TSST-1, Toxin Technology, Sarasota, FL). The anti-DR mAb L243 (Leinco Technologies, Ballwin, MO) was used as an additional control in these assays to determine the effects of blocking class II. Proliferation of the cells was determined after 3 days for TSST-1 stimulation and 5-7 days for TT stimulation. Cytofluorimetric assays For LAG-3-Ig binding assays, primary cells and tumor cells (3-5ϫ10 5 cells/sample) were incubated with LAG-3-Ig (10 µg/ml) or control human Ig (10 µg/ml) for 30 min on ice in PBS containing 1% FBS and 0.1% NaN 3 . Cells were then washed and stained with a goat anti-human Ig F(abЈ) 2 antibody conjugated to FITC (Biosource). Cells were also stained with a pan anti-DR,DP,DQ anti-class II antibody (PharMingen) and an isotype-matched control antibody (PharMingen) conjugated directly to FITC to determine class II expression. In experiments to analyze the phenotype of cells in the MLR cultures, cells from bulk MLR were stained with the following antibodies directly conjugated to a fluorochrome: class II, CD3, CD25, CD4, CD8, CD45RA and CD45RO (PharMingen). After incubation, cells were washed and resuspended in PBS buffer containing propidium iodide (10 µg/ml). Routinely, 5000-10,000 events per sample were acquired on a FACSort flow cytometer (Becton Dickinson) by gating on cells that excluded propidium iodide. Data analysis was performed using the Lysys II software.
Results
Binding studies
Previous studies have demonstrated that LAG-3 is another counter-receptor for class II (9, 10) . To analyze the binding characteristics of the soluble LAG-3-Ig generated by us, cytofluorimetry studies were performed using a panel of class II positive and negative human tumor cell lines and primary cells. As shown in Fig. 1 , LAG-3-Ig bound class II-expressing B cells such as Raji, LCL.721 and Daudi, myeloma cells such as RPMI 8226 and ARH77, DR7 allo-specific T cell clone TC-1, T cell lymphoma H9 and a monocytic line THP-1. The mean fluorescence intensity of binding of LAG-3-Ig to these cell lines was variable, with the highest observed binding to LCL.721. Human IgG was used as a control to demonstrate specificity of LAG-3-Ig binding. No specific binding of LAG-3-Ig to U937 cells, and a panel of other cell lines such as K562, T2 and L cells (data not shown) which lacked class II expression, was observed. These observations concurred with previous findings that expression of class II on cell surfaces correlated with binding of LAG-3-Ig.
LAG-3-Ig binding to primary human lymphocytes was investigated by dual fluorescence staining of PBL with LAG-3-Ig or human IgG1 (control for FcR binding ) and antibodies to T cell (CD4, CD8) or B cell (CD19) specific markers. As shown in Fig. 2 , the control human IgG1 protein demonstrated considerable background binding to a population other than the CD4-, CD8-or CD19-expressing lymphocyte populations. LAG-3-Ig bound predominantly to CD19 ϩ cells and to an unidentified population. Minimal binding of LAG-3-Ig to CD4-or CD8-expressing T cells was observed. In subsequent experiments, we have detected LAG-3-Ig binding to purified macrophages (CD64 ϩ ) and NK cells (CD56 ϩ ), cultured in vitro, in the presence of cytokines (data not shown).
LAG-3-Ig inhibited in vitro primary human MLR but not other modes of T cell activation
The in vitro MLR assay is regarded as a classical model to study T cell responsiveness to allo antigens, i.e. HLA class I and class II molecules and associated peptides expressed on stimulator cells (17, 18) . To explore the possible involvement or contribution of class II-LAG-3 interaction to T cell activation, the effect of adding soluble LAG-3-Ig to a MLR reaction was examined. As demonstrated in Fig. 3 , LAG-3-Ig inhibited the primary human MLR, by almost 80%, at a dose range of 0.1-10 µg/ml over days 5, 6 and 7 of the MLR reaction. In Ͼ10 independent MLR assays involving multiple donors, LAG-3-Ig reproducibly inhibited allo responses (data not shown). Inhibition of allo responses by LAG-3-Ig was observed consistently using either Raji cells or Ficoll-purified PBL as stimulators and whole PBL or CD4-enriched PBL as responders. Inhibition of proliferation in the presence of LAG-3-Ig varied from 50 to 90% at 10 µg/ml and in some MLR The one-way allogeneic MLR assay was set up as described in Fig.  3 . Fixed concentrations (10 µg/ml) of LAG-3-Ig, human IgG, CTLA-4-Ig or cyclosporin A (1 µg/ml) were added on a daily basis to the cultures for the duration of the assay (6 days). Proliferation of the cells was measured as described. Data is represented as c.p.m. Ϯ SEM from triplicate wells. Data shown is representative of three independent assays. S ϩ R, stimulators ϩ responders. Fig. 7 . Effect of LAG-3-Ig on cytokine production in human allogeneic MLR. One-way allogeneic MLR assay was set up as described using mitomycin C-fixed Raji cells stimulators (1ϫ10 4 cells/well) and primary PBL responders (1ϫ10 5 cells/well). Cells were incubated with a fixed concentration (10 µg/ml) of LAG-3-Ig, human IgG or CTLA-4-Ig for 5 days at 37°C in a humidified 5% CO 2 incubator. Amount of IL-2 and IFN-γ released into the supernatant of MLR cultures was measured using cytokine-specific ELISA kits. Data shown is representative of five independent assays. inhibition of the response was seen even at concentrations as low as 0.1 µg/ml. CTLA-4-Ig, a known modulator of CD28-dependent T cell activation, also inhibited the proliferation of PBL in the MLR.
Specificity of this inhibition mediated by LAG-3-Ig was confirmed using human IgG1 as a control for non-specific Fc receptor-mediated effects. Addition of human IgG1 protein to the assay medium had no significant effects on proliferation of responder cells compared to media controls in the MLR (Fig. 3) . As an additional control, in some experiments, human IgG1 was spiked along with LAG-3-Ig in the wells during the MLR (data not shown). Inhibition of the MLR seen in the presence of LAG-3-Ig was not significantly affected by spiking in, up to 100 µg/ml, human IgG1. These results suggested that the activity of LAG-3-Ig in the MLR was mediated by the LAG-3 portion rather than the Ig tail of the fusion protein.
Although LAG-3-Ig reproducibly inhibited allo MLR, it did not affect the proliferative response of PBL to stimulation with a number of other T cell activation antigens such as TT (Fig. 4A) , mitogens (phytohemagglutinin, concanavalin A, pokeweed mitogen, anti-CD3; data not shown) and superantigens (TSST-1) (Fig. 4B) . The fact that the proliferation of PBL in response to TT-or TSST-1-mediated stimulation was inhibited in the presence of an anti-DR mAb, but not LAG-3-Ig, suggested potential differences in the mechanisms of action of these two reagents that bound class II.
LAG-3-Ig inhibited in vitro xeno MLR
Besides human B cells, LAG-3-Ig also exhibited substantial binding to unactivated and mitogen-activated murine B cells (data not shown). To further understand the functional consequences of LAG-3-Ig interacting with a ligand such as class II, that is expressed on both human and murine B cells, a xeno MLR was developed using A20 murine B cells as stimulators and primary PBL as responders. As shown in Fig. 5 , LAG-3-Ig strongly inhibited the xeno response of human PBL to murine A20 cells in a dose-dependent manner. A maximum inhibition of 70% was seen with 5 or 10 µg/ml LAG-3-Ig, which titrated out to~50% inhibition at 0.5 µg/ml. As expected, CTLA-4-Ig and the anti-CD4 mAb, Leu 3A, also inhibited the xeno response. These results showed that as in the human system, by binding to class II expressed on murine A20 cells directly or by blocking self-restricted presentation of xeno antigens, LAG-3-Ig blocked a positive signal for human T cell proliferation.
LAG-3-Ig acted early in in vitro human MLR
In order to elucidate the mechanism of action of LAG-3-Ig in the MLR, LAG-3-Ig was added to the wells at various time points during the MLR at a fixed concentration of 10 µg/ml. As demonstrated in Fig. 6 , inhibition of the MLR was observed only when LAG-3-Ig was added to the wells at the start of the assay. No inhibition was observed, compared to the stimulators ϩ responders or human IgG controls, if LAG-3-Ig (10 µg/ml) was added at or later than 24 h after the initiation of the assay, i.e. after the T lymphocytes were committed to proliferate. Increasing the concentration of LAG-3-Ig, even up to 50 µg/ml, or cross-linking LAG-3-Ig with a second-step antibody, did not alter the results (data not shown). In contrast, inhibition of MLR by CTLA-4-Ig or cyclosporin A was achieved Fig. 8 . Effect of exogenous IL-2 addition to human allogeneic MLR. One-way allogeneic MLR assay was set up as described in Fig. 3 . Cells were incubated with a fixed concentration of LAG-3-Ig, human IgG or CTLA-4-Ig (10 µg/ml) for 5 days. IL-2 (100 U/ml) was added to the wells on a daily basis from the day of assay initiation (day ϭ 0). Proliferation of the cells was measured as described. Proliferation of responder PBMC in response to allo stimulation, in the absence of IL-2, is shown in the inset. Data is represented as c.p.m. Ϯ SEM of triplicate wells. Data shown is representative of three independent assays. even 48 h after initiation of assay. This observation raised the possibility that by binding to class II molecules, LAG-3-Ig either masked or blocked allo antigen presentation, resulting in inactivation or sub-optimal activation of naive responder cells.
LAG-3-Ig mediated inhibition of human allogeneic MLR resulted in decreased IL-2 production
To investigate whether the mechanism of action of LAG-3-Ig in blocking allo responses was due to a change in cytokine production, we measured the levels of IL-2, IFN-γ and IL-4 in the supernatants of MLR cultures on day 5 using cytokinespecific ELISA. A substantial reduction in the amount of IL-2 released in the supernatant of MLR cultures was reproducibly observed in the presence of LAG-3-Ig (Fig. 7) . The amount of IL-4 produced in the MLR cultures was below the detection limit of the ELISA assay in most MLR. In assays where IL-4 levels were measurable, no significant differences were seen in the amount of IL-4 released (data not shown). Further, the amount of IFN-γ produced, in the presence of LAG-3-Ig, varied in the different MLR. In 70-80% of the MLR, a 20-30% increase in IFN-γ production was measured. In others, IFN-γ amounts similar to control cultures were seen in the presence of LAG-3-Ig, even when IL-2 production was reduced by as much as 60%. In~20% of MLR, a small decrease of~20% in IFN-γ production was measured. We have confirmed that the enhanced IFN-γ production seen in the presence of LAG-3-Ig was not due to activation of NK cells in the responder population. In fact, LAG-3-Ig reproducibly inhibited killing of a variety of NK-specific targets by PBL (R. Nabioullin et al., manuscript in preparation). As expected, production of both IL-2 and IFN-γ was decreased in the presence of CTLA-4-Ig. At the gross cellular level, therefore, insufficient IL-2 production appeared to be one of the primary reasons for the lack of proliferation of responder cells in the presence of LAG-3-Ig.
Exogenous IL-2 supplementation does not overcome LAG-3-Ig-mediated inhibition of human allogeneic MLR To examine whether a reduction in the amount of IL-2 produced in the presence of LAG-3-Ig could be compensated by exogenous supplementation of recombinant human IL-2, MLR cultures were spiked with IL-2 (100 U/ml) on a daily basis for 5 days. As shown in Fig. 8 , addition of IL-2 simultaneously with LAG-3-Ig (10 µg/ml, day 0), or after LAG-3-Ig addition (days 1-5), did not overcome the inhibition mediated by LAG-3-Ig. On the other hand, inhibition of the MLR mediated by CTLA-4-Ig was readily reversed during the first 48 h of the assay by the addition of exogenous IL-2 (19). It appears that unlike CTLA-4-Ig, which blocks T cell proliferation by interfering with the CD28-dependent co-stimulatory signals (20) , the mechanism of action of LAG-3-Ig does not depend solely on inhibition of IL-2 production. Further, the inability of IL-2 to correct the proliferative defect in the MLR has been confirmed to be not mediated by the induction of death of either the stimulating or responding populations by LAG-3-Ig (data not shown). Fig. 9 . Phenotypic analysis of effector cells generated in primary human allogeneic MLR. The one-way allogeneic MLR cultures were incubated with a fixed concentration of LAG-3-Ig, human IgG or CTLA-4-Ig (10 µg/ml) as described. On day 5 of the assay, cells were collected and stained as described with the following antibodies: CD4-, CD8-and CD19-phycoerythrin, and CD25-FITC. Viable cells were acquired and analyzed using the Lysys II program on the FACSort. Percentage of cells within each quadrant is indicated.
Addition of LAG-3-Ig to an allo MLR resulted in decreased activation of CD4 ϩ T cells To further examine the specific effects of soluble LAG-3-Ig in a MLR, cytofluorimetric analysis of the phenotype of responder cells was performed on day 5 of the MLR. As demonstrated in Fig. 9 , a decrease in the percentage of CD4 ϩ T cells expressing the IL-2 receptor (CD25) was observed in the presence of LAG-3-Ig (22%) compared to the stimulator ϩ responder control (36%). Additionally, a decrease in the mean fluorescence intensity of expression of the CD25 receptor on CD4 cells exposed to LAG-3-Ig was observed. Inhibition of CD25 expression on CD4 T cells was also seen in wells treated with CTLA-4-Ig (18%). No significant decrease in CD25 expression on CD8 ϩ T cells or CD19 ϩ B cells was observed in the presence of LAG-3-Ig. In some MLR, a decrease in the overall percentage of CD3 ϩ T cells was also observed, in the presence of LAG-3-Ig (data not shown). Lack of a positive signal required for T cells to proliferate appeared to influence the overall numbers of viable T cells by day 5 of the MLR. These results suggested that in the presence of LAG-3-Ig, insufficient IL-2 production was accompanied by decreased activation and clonal expansion of a subset of T h cells.
LAG-3-Ig does not inhibit the function of allo-reactive cytotoxic T cells
To evaluate the effect of LAG-3-Ig on the activity of cytolytic T cells, PBMC stimulated by allo APC, in the presence or absence of LAG-3-Ig, were tested for their ability to lyse 51 Crlabeled stimulator cells (data not shown). No differences were observed in the cytolytic potential of effector T cells generated in the presence of LAG-3-Ig, compared to effectors generated in the presence of human IgG or media control. Further, no decrease in the percentage of target cell lysis was observed when LAG-3-Ig was added to the effectors and target cells during the period of the 51 Cr -release assay (data not shown). This suggested that LAG-3-Ig had the potential to block certain modes of T cell activation, or certain effector functions of T cells, mainly CD4-mediated rather than CD8-mediated.
Discussion
To evaluate the contribution of LAG-3-class II interaction in the regulation of T cell-mediated immune responses, a soluble fusion molecule of the extracellular domain of LAG-3 and human IgG1 (hinge, CH2 and CH3) was generated. As demonstrated, LAG-3-Ig bound primarily to class II-expressing human and murine B cells. Specificity of LAG-3-Ig binding to different cells was shown by saturation of binding and by competing binding of LAG-3-Ig with a soluble LAG-3 protein comprised of the four extracellular domains only and with blocking mAb against LAG-3 (data not shown). Given the fact that LAG-3-Ig interacted with class II, ability of LAG-3-Ig to bind across species suggested that LAG-3-Ig was interacting with monomorphic residues on class II (21) .
LAG-3 has been proposed by Huard et al. (12) to be involved in down-modulation of T-dependent immune responses. These authors demonstrated that cross-linking soluble LAG-3-Ig fusion protein inhibited the proliferation of a CD4 ϩ T cell clone to a variety of TCR-dependent and independent stimuli in the absence of exogenous APC. They concluded that aggregation of class II molecules expressed on the T cell clone, by LAG-3-Ig, resulted in the delivery of a negative signal. Although inhibition of proliferation of a TT-dependent T cell clone by soluble LAG-3-Ig has been observed (Dr H. Offner, pers. commun.), no effect of crosslinked or soluble LAG-3-Ig on class II-restricted, antigendependent stimulation of PBL was seen in these studies. The most likely explanation for these observations is the differences in the phenotype of the responding population in allogeneic versus antigen-dependent activation of T cells (17) . Cells responding to a primary allo or xeno stimulus are usually of the naive phenotype, as opposed to memory cells which respond to a recall antigenic stimulus. Alternatively, LAG-3-Ig may be effective only in blocking allo class IIrestricted responses, as opposed to self class II-restricted responses. Subtle differences, however, in the signaling machinery of clonal versus primary cells may also be responsible for the observed effects.
The primary effector cells perturbed by LAG-3-Ig in both allo and xeno MLR have been identified to be T cells. In the MLR, effector T cells are activated either directly by the allo HLA class I and class II proteins and associated peptides on stimulator cells, or indirectly by the processing and presentation of allo-HLA proteins by autologous APC in the context of self-HLA molecules (22, 23) . The fact that LAG-3-Ig inhibited MLR performed with CD4 enriched PBL (depleted of CD8 cells, autologous APC and NK cells) as the responders, suggested blocking allo-restricted presentation as an important mechanism of LAG-3-Ig-mediated effects. Lack of inhibition of recall responses by LAG-3-Ig also supports the notion that the effect of LAG-3-Ig on self-restricted presentation of allo antigens if any, should be minimal. Further, although membrane LAG-3 expression is detected only 48-72 h after activation of PBL (data not shown), soluble LAG-3-Ig was effective in blocking the MLR only if added within the first 24 h of the assay, when T cells undergo commitment to proliferate. Addition of soluble LAG-3-Ig after the first 24 h had no effect on the outcome of the assay. This suggested that direct presentation of allo antigens to responder T cells was the point of intervention for LAG-3-Ig.
Mechanistically, interaction of LAG-3-Ig with class II may interfere with the interaction of the CD4 co-receptor-TCR complex with class II, or with the multimerization of class II, steps which are pre-requisite for effective antigen presentation and signal transduction.
We excluded the possibility that engagement of FcR on accessory cells by the IgG1 tail of LAG-3-Ig was responsible for the observed inhibition of proliferation by adding aggregated human Ig simultaneously with LAG-3-Ig to the MLR cultures. Human Ig did not overcome or diminish the inhibition seen in the MLR in the presence of LAG-3-Ig. Further, the lack of effect of LAG-3-Ig on other modes of T cell activation ruled out Fc-mediated killing as a possible mechanism of action in the MLR. Analysis of the mechanism of action of LAG-3-Ig in the MLR showed that the activation of responder cells was not completely impaired. In terms of cytokine production, a substantial decrease, but not complete abrogation, of IL-2 production was observed. This was accompanied with minimal changes in the levels of expression of IL-4 and IFN-γ. In fact, in some MLR reactions an increase in IFN-γ production was seen. We have confirmed that the source of this enhanced IFN-γ production is not the NK cells in the MLR cultures (data not shown). Furthermore, phenotypic analysis of the effector cells from MLR cultures showed a significant decrease in IL-2 receptor (CD25) expression exclusively on CD4 ϩ cells but not on CD8 ϩ cells in the presence of LAG-3-Ig. IL-2 is an important cytokine for the autocrine, as well as paracrine stimulation and clonal expansion of T cells. Decrease in IL-2 receptor expression, therefore, may be a consequence of lack of sufficient IL-2 production in the presence of LAG-3-Ig. In this regard, the inability of exogenously added IL-2 to overcome the inhibition mediated by LAG-3-Ig may well be due to insufficient IL-2 receptor expression by the CD4 ϩ T cells. The above findings strongly supported the notion that lack of activation and proliferation of CD4 ϩ T cells in the MLR was due to inhibition of allorestricted presentation by LAG-3-Ig. Further, the data suggested that unlike CTLA-4-Ig, decreasing IL-2 production by affecting components of the IL-2 transcriptional or translational pathway was not the primary target of action of LAG-3-Ig.
An intriguing observation was the dichotomy in the effects of LAG-3-Ig on CD4 ϩ T cells versus CD8 ϩ T cells in MLR cultures. Unimpaired or enhanced IFN-γ production in the MLR cultures in the presence of LAG-3-Ig and normal IL-2 receptor expression on CD8 ϩ cells suggested that activation of CD8 cells, probably by direct class I alloantigen presentation, was not affected by the presence of LAG-3-Ig. Additional evidence for this hypothesis was provided by the observation that allo-restricted cytolytic T cell responses, largely mediated by CD8 ϩ cells, were unchanged in the presence of LAG-3-Ig.
In summary, the expression profile of LAG-3 predominantly on NK cells and T cells, combined with the expression of LAG-3 ligand on B cells, macrophages and NK cells, makes this system an attractive target for immune intervention. Data presented in this report strongly supports a role for LAG-3-MHC class II interaction in promoting CD4 ϩ T cell allo responses. 
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